Design Therapeutics (DSGN) Cash from Investing Activities (2020 - 2026)

Design Therapeutics has disclosed Cash from Investing Activities across 7 years of filings, most recently posting -$7.6 million for Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at -$7.6 million, down 196.43% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.5 million (down 76.12% YoY), and the FY2025 annual result was $22.9 million, down 47.87% from the prior year.
• Cash from Investing Activities came in at -$7.6 million for Q1 2026 at Design Therapeutics, up from -$11.6 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $27.3 million in Q2 2024 to a low of -$157.0 million in Q2 2022.
• The 5-year median for Cash from Investing Activities is $5.6 million (2023), against an average of -$6.4 million.
• Across the five-year window, Cash from Investing Activities slumped 1157.22% in 2022 and soared 4666.43% in 2023, its largest moves.
• Design Therapeutics' Cash from Investing Activities stood at -$1.1 million in 2022, then surged by 626.04% to $5.6 million in 2023, then slumped by 67.02% to $1.8 million in 2024, then tumbled by 732.26% to -$11.6 million in 2025, then soared by 34.48% to -$7.6 million in 2026.
• The last three Cash from Investing Activities figures came in at -$7.6 million (Q1 2026), -$11.6 million (Q4 2025), and $6.5 million (Q3 2025), per Business Quant data.